John joined Tizona as Vice President of Antibody Development in 2016. In his role, he is responsible for antibody discovery and engineering. Prior to joining Tizona, John was at Gilead Sciences, where he oversaw antibody discovery and engineering. In addition, John was a project team leader for several therapeutics antibody programs ranging from early stage through Investigational New Drug-enabling development. Previously, he held several positions of increasing responsibility at XOMA LLC. At XOMA, he was responsible for all aspects of biomolecular interaction analysis required for the discovery and development of therapeutic antibodies. He also led XOMA’s insulin receptor antagonist program (XOMA 358) from inception through lead selection.

John received his Ph.D. in Biology from University of California at Santa Cruz and completed his postdoctoral research at the University of Colorado at Boulder. John has been published in numerous peer-reviewed journals and has U.S. patent and U.S. applications relating to therapeutic antibodies.